

CURRICULUM VITAE

Name : Marwan Assad Masri

PRESENT POSITION:

CEO Transmedical s.a.l
CEO Transmedical For Life
President of the Asian Society of Transplantation (AST).
Vice President and President elect of the Middle East Society for Organ Transplantation (MESOT)
Coordinator of the Mediterranean Stem Cell therapy for liver disease
Member of the committee of Medical Ethics in Transplantation.
Board member of the joint Task force (WHO, Kidney Foundation and Transplant Society).
Board Member of Global alliance for transplantation (GAT).
Country representative in the Transplant society (TTS)
Board Member Mediterranean Transplant Network
Member of the custodian group of the Istanbul declaration
Director of the Quality Assurance Scheme In transplantation For the Middle East, Gulf, Asian and African Countries
Professor of Immunology
Head of the MESOT registry
Associate editor Experimental and clinical transplantation.
Editorial board member of Transplant Proceedings
Guest editor Transplant Proceedings 2002.
Guest editor Molecular Immunology 2003.
Associate editor Drug and therapeutic
Associate editor I.J. of enzymology
Associate editor China medical Journal

Major Degrees:

- a) Fellowship, Department of Oncology University of Calgary and Tom Backer Cancer Center (Foot Hills Hospital) Calgary Alberta Canada. 1984
- b) PH.D. Immunopathology Faculty of Medicine Department of Medical sciences University of Calgary, Calgary Alberta Canada (1983).
- c) MSc. Immunopathology Faculty of Medicine Department of Medical sciences University of Calgary, Calgary Alberta Canada (1980).
- d) B.Sc.; Biology Chemistry Faculty of Science American university of Beirut (AUB) Beirut Lebanon (1972).

Employment Record:

1. CEO Transmedical s.a.l (since 2001)
2. CEO Transmedical International (since 2001)
3. CEO Transmedical For Life (since 2009)
4. 1994-2006:
 - Head of Laboratories at Rizk hospital (Beirut Lebanon).
 - Head of Immunology and Immunopathology Rizk Hospital.
 - Head of Care evaluation committee at Rizk Hospital (quality assurance)
5. 1988-1994:
 - Director of Transplant Unit Mafrq Hospital; Director Emirates Institute For Medical Research
 - Professor Medical School University of the United Arab Al Ain UAE.
 - Director of the Quality Assurance Scheme in transplantation For The Middle East, Gulf and African Countries;(appointed by the Arab Society of Nephrology and Kidney Transplantation).
 - Consultant/Advisor for Sandoz Pharma Switzerland on Immunosuppression.
 - Consultant/Advisor for IVAX Corporation USA.
 - Consultant/Advisor for Global Pharmaceuticals (Switzerland)
 - Advisor for Roche Pharmaceutical.
 - Advisor for Exir Pharama Iran
 - Advisor for the MESOT organization.
 - Advisor Sigmapharma Brazil
 - Coordinator of all congresses for the Arab society, Asian Society and Middle East Society of Organ Transplantation.
6. 1986-1988:

Deputy Director and financial manger EIMR.
7. 1984-1986:

Head of immunopathology and tumor immunology and deputy head of Transplant unit at the Mafrq Hospital and the Emirate Institute For Medical Research (EIMR) Abou Dhabi United Arab Emirates. (UAE).
8. 1982-1984:

Laskin Postdoctoral Fellow, Department of Oncology University of Calgary and Tom Backer Cancer Center Calgary Alberta Canada.
9. 1980-1983:

Research assistant Department of Pathology and Medical Immunology, Faculty of Medicine University of Calgary, Calgary Alberta Canada.
10. 1980-1982:

Part time in the department of Laboratories at Research and Development, Foothills Hospital Calgary Alberta Canada

11. 1980-1982 :

Teaching assistant Department of Pathology and Immunology, Faculty of Medicine University of Calgary, Alberta Canada.

Research Activities:

- 1) Toxicity studies in vitro, animal and human models mainly for immunosuppressive drugs that "Rapamycin, Fk-506, Cell Cept, and drugs that are underdevelopment Such as Equoral, FTY720, and anti adhesion molecules.
- 2) Production, purification and characterization of Monoclonal antibodies with a special interest in Tumor associated antigens and immune competent cell Surface antigens.
- 3) Experimental transplantation of Islets.
- 4) Stem Cell Research
- 5) Organ preservation.
- 6) Genetic mapping for diagnostics
- 7) Drug evaluation

SOCIETIES:

1. Asian Transplant Society (president).
2. Middle East Society for Organ Transplant (MESOT vice president and President Elect).
3. International Transplant Society (representative)
4. Arab Nephrology and Kidney Transplant Society (Council Member).
5. Board Member GAT
6. European Dialysis and Transplant Association.
7. European Transplant Society ESOT "associate member"
8. Member of the Board of Trustees Chronic Care Center, Beirut Lebanon.
9. President of the AUB Alumni Association, Abu Dhabi Branch.
10. Elected member to New York Academy of Science
11. Board Member of the international task force on Pharmacokinetics and Pharmacogenetics.

Publications:

Human clinical studies:

1. Jerry LM. Masri Marwan Philips TM, Sikora L, Jones C, Dixon W and Demetrick D. Markers of human malignant melanoma: Towards biology of host-tumor response. In: Tumor markers

- in clinical practice concepts and applications. Ed. AS Daar, Blackwell Scientific, Oxford UK. 428-496 (1987).
2. Sewchand LS, Masri MA, Fritz GA, Boyd Nd, and Rowlands S. Fibrinogen and the ultra-long range interaction of human erythrocytes. *Cell Biophys.* (1984).
 3. Masri MA, Shakuntala V, Dhawan IK, Hays K, Karim T, and Pingle A. Cyclosporine dosage according to pharmacokinetics profiles leads to better graft and patient survival rates and a decrease in cyclosporine consumption. *Transplant. Proc.* 24: 1718 (1992).
 4. Masri MA, Dhawan IK, Hayes K, Zahir M, Shakuntala S, Shanwaz M and Pingle A. The relevance of HLA matching on graft survival, patient survival, and graft function in the live related renal transplant patients treated with cyclosporine. *Transplant Proc.* 24: (1992).
 5. Hayes K, Shakuntala V, Pingle A, and Masri MA. Safe use of A-Cyclovir (Zovirax) in renal transplant patients on cyclosporine A (CYA) therapy: Case reports. *Transplant Proc*, 24(5) 1926, 1923
 6. Pingle A, Shakuntala R.V, Zahir MB, Shanwaz M, Masri MA, Hayes K, Dhawan IK. Factors responsible for rejection of potential kidney donors in a live related transplant program. *Transplant Proc.* 24:(1992).
 7. Masri MA, Dhawan IK, Shakuntala V, and Pingle A. Cyclosporine monotherapy vs. conventional therapy in live related renal (LRD) transplant patients: A one center retrospective pilot study. *Transplant Proc.*:25:2248-2249 (1993).
 8. Masri MA, Dhawan IK, Hays K, Shanwaz M, Zahir M, Shakuntala V, Yasin M and Pingle A. Transplantation in the United Arab Emirates. *Transplant Proc.*25:2358 (1993).
 9. Masri MA, Shakuntala V, Dhawan IK, Shanwaz M, Zahir M, Yasin M and Pingle A. Pharmacokinetics of Cyclosporine in renal transplant patients on Diltazim. *Transplant Proc* 26(4): 1921, 1994
 10. Masri MA, Shakuntala V, Dhawan IK, Shanwaz M, Zahir M, Yasin M and Pingle A. Erythropoietin and plasmapheresis in the highly sensitized patients. *Transplant Proc.*: (1994).
 11. Abou Sharhea A and Masri MA. Epidemiology of Psoriasis in the U.A.E. *British Journal of Dermatology*: 1994).
 12. Al Attia H M O.B. Gatee, S. George, and M A Masri . Rheumatoid Arthritis: A population sample in the Gulf: Clinical observations. *Clinical Rheumatology*, 1: 506-510: 1994.
 13. Masri MA, Quality Assurance in transplantation. *African Journal of Health Sciences*. 1: (1994).
 14. Yassin I. El Shahat, Shakuntala V, Zahir MB, Shah Nawaz, IK Dhawan Masri MA, Hayes K and Pingle A. Treatment of end-stage of renal failure in Abu Dhabi, united Arab Emirates. *Saudi journal of kidney Diseases and Transplantation*. 5(3): 384-395, 1994.
 15. Masri MA, Barbari A, Stephan A, Kamel G, Frem G, Younan F, Rizk S, Moubarak R and A Karam. Cyclosporine pharmacokinetics in stable renal transplant patient: Effect of formulation, Sandimmun vs. Consupren vs. Neoral. *Transplant Proc.*(1995)
 16. Masri MA, Kamel G, Frem G, Karam A, Barbari A and Stephan A. current status of organ transplantation in Lebanon. *Bulletin of the Asian Society of Transplantation*. 3:18, 1995.
 17. Masri MA, Barbari A, Kamel G, Karam A and Stephan A. Correlation between cyclosporine pharmacokinetics and immunological parameters in dialyzed patients awaiting transplantation. *Transplant Proc.*(1997).
 18. Kamel G, Barbari A, Stephan A, Younan F and Masri MA. Donor specific transfusion (DST) under the new cyclosporine formulation (Consupren, CON) Vs Azathioprine (Imuran, IM). *Transplant Proc.*(1997).

19. Stephan A, Barbari A, Masri MA, and Kamel G. A two year study of the new cyclosporine (CYA) formulation Consupren in de novo renal transplant patients. Transplant Proc. (1998).
20. Barbari A, Stephan A, Kamel G, Kilany H, and Masri MA. Experience with new Cyclosporine formulations Consupren and Neoral in renal transplant patients. Transplant Proc. (1997).
21. Masri MA, Kamel G, Barbari A, Kilany H, Rizk S and A Stephan. Immunosuppressive therapy in renal transplant patients according to patient immunological status. Transplant Proc.(1997).
22. Kamel G, Stephan A, Barbari A, Karam A and Masri MA. Transplantation at Rizk Hospital: 10 years experience. Transplant Proc. (1998)
23. Masri MA, Stephan A, Barbari A, Rizk S and Kamel G. Future trends in transplant therapy monitoring. Transplant Proc. (1998).
24. Masri MA, Stephan A, Barbari A, Rizk S, Aoun S and Kamel G. Safe and cost effective conversion from Neoral to Consupren soft gelatin capsule in stable renal transplant patients. Transplant Proc. (1999).
25. Stephan A, Barbari A, kamel G, Aoun S, and Masri MA. A one Center Experience with a short course of Mecophenolic Acid. Transplant Proc.(1999).
26. Masri MA, Logical approaches to transplant patient therapy monitoring. Transplant Proc. (1999).
27. Masri MA. Cyclosporine formulations is there really a difference? Transplant Proc. (1999).
28. Masri MA Cytokines in graft acceptance and rejection. Transplant Proc. (1999).
29. Barbari A. , Masri M. A , Stephan A., Kilany H., Rizk S. and Kamel G. Lymphocyte Cyclosporine Pharmacokinetic VS. Whole Blood Pharmacokinetic Monitoring: Correlation With Histological Finding. Transplant Proc.2001
30. Stephan A., Masri M.A., Barbari A., Kamel G. and Kilani H.. Therapeutic Drug Level Monitoring For Mycophenolate Mofetil (MMF) Is It Justified? Transplant Proc. 2001
31. Masri M.A., Barbari A., Stephan A., Rizk S., MSc. and Kamel G. Cytokines Gene Polymorphism In a Lebanese Transplant Population And Its Impact On Graft Survival: A One Center Pilot Study. Transplant Proc.2001
32. Barbari A., Joubran N., Dagher O., Stephan A., Kilani H., Masri M., and Kamel G. Donor Specific Transfusion (DST) In Kidney Transplantation: Effect Of Different Immunosuppressive Protocols On Graft Outcome. Transplant Proc. 2001
33. Masri M.A.. The mosaic of immunosuppressive drugs. Molecular Immunology.39:1073-1077, 2003
34. Stephan A; Barbari A; Kamel G; A Jaoude F; Kilani H; Ghanem G and A. Karam. ACE Inhibitors and the hypoperfused graft. Transplant Proc 2003, (in press).
35. A. Barbari, A. Stephan, M. Masri, N. Mourad, G. Kamel, A. Karam and H. Kilani.Cyclosporine A Lymphocyte Maximum Level (LTmL)A New alternative for CyA monitoring in kidney transplantation. Transplant Proc 2003, (in press).
36. A. Barbari, A. Stephan, M. Masri, N. Mourad, G. Kamel, A. Karam, H. Kilani and I A Daya. Cyclosporine A Lymphocyte level and Lymphocyte count: New guidelines for Tailoring Immunosuppressive Therapy. (transplant proc 2003).
37. Kamel G; Stephan A; Salmeh P; Zeineh S; Barbari A; Kilani H; Karam A. Textiloma in a kidney recipient: A rare complication. (MESOT 2002).
38. Kamel G; Stephan A; Salmeh P; Zeineh S; Barbari A; Kilani H; Karam A; Khoury J and Mokhbat. Obstructive anuria due to fungal Bezoar in a renal graft recipient.
39. Masri MA. Do we need less immunosuppressive therapy in Middle Eastern patients?: Iranian Journal of Urology. in press 2004

Animal Models for the evaluation of toxicity and efficacy of new drugs:

40. Masri MA, Boyd Nd and Mandin H. The role of fibrinogen in the permeability of the perfused isolated dog kidney. *Kidney Int.* 27:807. (1985).
41. Masri MA, Boyd ND, Alexander F, Barabas AZ and Klassen J. Irreversible attachment of immunoglobulins and F (ab) 2 fragments to their specific cell membrane antigens. *Transplantation.* 30 (5):373 (1980).
42. Daar AS, Pingle S, Naiem M and Masri MA. Histological changes in atrophic spleens of mice treated with Cyclosporine A. *Transplant. Proc.* 21:4329 (1987).
43. Masri MA, Naiem M and Daar AS. Age and dose dependence of Cyclosporine G and Cyclosporine A Nephrotoxicity in BALB/c mice. *Transplant. Proc.* 20 (1987).
44. Masri MA, Pingle S, Naiem M and Daar AS., Immunopathological changes in spleens of BALB/c mice treated with either cyclosporine A (CSA) or cyclosporin G(Nva2-cyclosporin, CSG). *Transplant Proc.* 21: 952 (1988).
45. Masri MA, Pingle S, Naiem M, and Daar AS. Cyclosporine A, cyclosporin G:A comparative study of survival, hepatotoxicity, nephrotoxicity, and splenic atrophy in BALB/c mice. *Transplant. Int.* 1:13 (1988).
46. Masri MA. Comparative study of skin graft survival rates in BALB/c mice treated with either cyclosporine A, cyclosporine G, or 1/1 combination of both. *Transplant. Proc.* 24:1661 (1992).
47. Masri A. Marwan. Comparative study of toxicity and efficacy of cyclosporine G(OG 37), FK-506 and Rapamycin in BALB/c mice with fitted skin grafts. *Transplant Proc.*(1995).

Basic Research

48. Masri MA, Masri SA, and Boyd. Isolation of Human fibrinogen of high purity in high yield using polyethylene glycol 1,000. *Thromb. Hemostat.* 49: (1983).
49. Masri MA. Cyclosporine blood level monitoring by three specific methods, RIA H3, RIA I125, and fluorescence polarization: Comparison of accuracy, cost, reproducibility and percent recovery. *Transplant Proc.* 24: 1716 (1992).
50. Masri MA. Sandimmun blood level monitoring. Booklet: Sandoz Pharma Press, Basle Switzerland. (1991).
51. Masri MA, Barbari A, Stephan A, Rizk S and Kamel G. A Comparative study of HLA alleles frequency in Lebanese, Arabs, United Arab Emirates and East Indian populations. *Transplant Proc.*(1997)
52. Masri MA, Barbari A, Stephan A, Rizk S, Kilany H, and Kamel G. Measurement of Lymphocyte Cyclosporine levels in transplant patients. *Transplant Proc.*(1998).
53. M.A. Masri, T. Andrysek, V. Matha The cons and pros of immunosuppressive drug therapy blood level monitoring *Transplant Proc* 2003
54. Masri MA, Sylvana Rizk, T. Andrysek, V. Matha. cross-reactivity of anti-cyclosporine A monoclonal with its sulphate metabolite: an in vitro study. *Molecular Immunology* 39: 1059-1060, 2003 .
55. Masri M.A.Barbari A, Stephan A, Rizk S and Kamel G. Technical limitation in therapeutic drug monitoring: *Transplant Proc.* In press 2003

56. Marwan Masri. The MESOT transplant Registry: Experimental and clinical transplantation Jan 2005
57. Barbari, A. Stephan, M. Masri, N. Mourad, G. Kamel, A. Karam, H. Kilani and I A Daya. Cyclosporine A Lymphocyte level and Lymphocyte count: New guidelines for Tailoring Immunosuppressive Therapy. Transplant proc, 35:2742-2744, 2003.
58. An assay for the determination of Sirolimus levels in the lymphocyte of transplant patients. Marwan Masri, Sylvana Rizk , Antoine Barbari, Antoine Stephan, Gaby Kamel and Michael Rost TransMedical Research Institute P.O Box 113-6290 Hamra Beirut Lebanon , Lebanese Institute of Renal Disease (LIRD), Beirut Lebanon, South Bohemian University, Faculty of Agriculture, Department of Applied Mathematics and Informatics, Ceske Budejovice, Czech Republic. (In Press May 2007 Transplant Proc)
59. A novel assay for the determination of Cyclosporine (CYA) levels in the saliva, dental plaque and the gum biopsy of renal transplant recipients using a patent drug extraction reagent MERI (Beirut Lebanon). Marwan Masri, Samia Abou Jaoude , Sylvana Rizk, Michael Rost , Antoine Barbari, Antoine Stephan, and Gaby Kamel Transmedical Research Institute s.a.l. Beirut Lebanon, the Lebanese university School of Dentistry Beirut Lebanon , South Bohemian University, Faculty of agriculture, Department of Applied Mathematics and Informatics, Ceske Budejovice, Czech Republic and Lebanese Institute of Renal disease (LIRD) Beirut Lebanon. (In Press May 2007 Transplant Proc)
60. An assay for the determination of sirolimus levels in the lymphocyte of transplant patients. Masri M, Rizk S, Barbari A, Stephan A, Kamel G, Rost M. Transmedical Research Institute, Beirut, Lebanon. Marwan.masri@mysalima.com Transplant Proc. 2007 May;39(4):1204-6.

Clinical, bioavailability/bioequivalence evaluation of new products:

61. Stephan A, Barbari A, Masri MA, Frem G, Kamel G, Rizk S, Moubarak R, Khoury W and A Karam. Evaluation of new cyclosporine formulation Consupren in renal transplant patients. Transplant Proc.(1995).
62. Stephan A, Masri MA, Barbari A, Kilany H, Rizk S and Kamel G, A one year comparative study of Sandimmun Neoral Vs Consupren in de novo transplant patients. Transplant Proc. (1998).
63. Masri M.A. Andrysk T. Matha V. 4 way crossover comparative study of Equoral vs. Neoral in healthy volunteers. Transplant Proc.2001
64. Masri MA, T Andrysek, V. Matha: The role of generic in transplantation. Tissue antigen in press 2002
65. Masri M.A. Bioavailability vs. bioequivalence: the Cyclosporine model. Experimental and clinical transplantation 2004
66. Marwan A. Masri, Mehmet Haberal, Adib Rizvi, Antoine Stephan, Nevzat Bilgin, Anwar Naqvi, Antoine Barbari, Gaby Kamel, Naqi Zafar, Remzi Emiroğlu, Turan Çolak, Kashif Manzoor, Vladimir Matha, Vojtech Kamarad , Sylvana Rizk and Ali Hazieme. The

- pharmacokinetic of Equoral[®] vs. Neoral[®] in stable renal transplant patients: A multi national multi-center study Transplant Proc. 2004
67. Marwan A. Masri, Tomas Andrysek, Sylvana Rizk and Vladimir Matha. The Role of Generics in transplantation. TM-MMF vs Cellcept in Healthy volunteers. Transplant Proc. 2004
 68. Andrysek T., Masri M., Jegorov A., Veselsky Z., Matha V. Equoral, new cyclosporine drug delivery system, versus Neoral: A bioequivalence study in healthy volunteers. Transplant Proc 35:203-5 2003
 69. Masri MA. The generics in transplantation and the rules on their use. Experimental and Clinical Transplantation. 1: 65-68
 70. Marwan A. Masri. Bioavailability versus bioequivalence: The Cyclosporine model. Experimental and clinical Transplantation. 1, 119-124, 2003
 71. Marwan A. Masri, Mehmet Haberal, Adib Rizvi, Antoine Stephan, Nevzat Bilgin, Anwar Naqvi, Antoine Barbari, Gaby Kamel, Naqi Zafar, Remzi Emiroğlu, Turan Çolak, Kashif Manzoor, Vladimir Matha, Vojtech Kamarad, Michel Rots, Sylvana Rizk and Ali Hazime. Switch ability of Neoral with Equoral according to FDA rules and regulations. Transplant Proceedings 2005.
 72. Bioavailability of a new generic formulation of Mycophenolate Mofetil MMF 500 (Les laboratoires des Medicaments Sterile Medis Tunisia) vs. CellCept (Roche Switzerland) in adult healthy volunteers.
Marwan A. Masri, Sylvana Rizk, Mouez Lidine Elleh Attia, Hanene Barbouch And Michael Rost .TransMedical drug evaluation center Beirut Lebanon ,Laboratoires Medis Tunis and South Bohemian University, Faculty of Agriculture, Department of Applied Mathematics and Informatics, CeskeBudejovice, Czech Republic. (In Press May 2007, Transplant Proc).
 73. Marwan Masri, Sylvana Rizk Mousa Mousa and Michael Rost. An experimental evaluation of relative bioavailabilities of two formulations of atorvastatin 20 mg tablets in healthy human subjects. Transmedical s.a.l Beirut Lebanon, Benta s.a.l Beirut Lebanon and South Bohemian University

Pattents:

1. Method for the monitoring of drugs at their site of action
2. kits to extract drugs from cell and tissue.

Diagnostics:

1. ELIZA kits to monitor Cyclosporine in Blood
2. ELIZA kits to monitor MPA in blood

Curriculum Vitae

Name : Sylvana Rizk

Address : Transmedical s.a.l

PO Box : 113-6290 Beirut Lebanon

Tel : 961 1 737705

Tel : 961 3 973439 (MOBILE)

Email : sylvanarizk@transmedicals.com

Major Degrees:

- 1- BSc. In Laboratory Medicine from Lebanese University
- 2-MSc in laboratory medicine Theses Title 'Sexually Transmitted Diseases'
- 3-Associate Research Fellow Immunology and Transplantation .
- 4-Auditor certification Quality assurance program ISO9001:2000. (QMI Canada)

Current position (since 1/6/2003):

1. Head of quality control program for Transmedical s.a.l
2. Research Fellow at Transmedical s.a.l beirut lebanon

Employment:

1. 1993-1994: Laboratory Department, Lebanese Hospital, Beirut Lebanon.

Duties: Performing all laboratory tests at the Bacteriology department.

2. 1994-2006: Research associate, Department of Immunology and Transplantation, at Rizk hospital, Beirut Lebanon.
3. 2003-2006 Part time consultant for the quality control program at Transmedical s.a.l Beirut Lebanon

Duties: Design, develop and implement protocols for therapeutic drug monitoring and immunological tests.

4. 2002 - present: head of quality assurance program Transmedicals Beirut Lebanon

Duties: insure the quality of Clinical trials

Validation of data

Validation of Transplant Centers and Laboratories

Publications:

74. Stephan A, Barbari A, Masri MA, Frem G, Kamel G, Rizk S, Moubarak R, Khoury W and A Karam. Evaluation of new cyclosporine formulation Consupren in renal transplant patients. Transplant Proc.(1995).
75. Masri MA, Barbari A, Stephan A, Kamel G, Frem G, Younan F, Rizk S, Moubarak R and A Karam. Cyclosporine pharmacokinetics in stable renal transplant patient: Effect of formulation, Sandimmun vs. Consupren vs. Neoral. Transplant Proc.(1995)
76. Masri MA, Barbari A, Stephan A, Rizk S and Kamel G. A Comparative study of HLA alleles frequency in Lebanese, Arabs, United Arab Emirates and East Indian populations. Transplant Proc.(1997)
77. Stephan A, Masri MA, Barbari A, Kilany H, Rizk S and Kamel G, A one year comparative study of Sandimmun Neoral Vs Consupren in de novo transplant patients. Transplant Proc. (1998).
78. Masri MA, Kamel G, Barbari A, Kilany H, Rizk S and A Stephan. Immunosuppressive therapy in renal transplant patients according to patient immunological status. Transplant Proc.(1997).
79. Masri MA, Barbari A, Stephan A, Rizk S, Kilany H, and Kamel G. Measurement of Lymphocyte Cyclosporine levels in transplant patients. Transplant Proc.(1998).
80. Masri MA, Stephan A, Barbari A, Rizk S and Kamel G. Future trends in transplant therapy monitoring. Transplant Proc. (1998).
81. Masri MA, Stephan A, Barbari A, Rizk S, Aoun S and Kamel G. Safe and cost effective conversion from Neoral to Consupren soft gelatin capsule in stable renal transplant patients. Transplant Proc. (1999).
82. Barbari A. MD, Masri M. A PhD, Stephan A.,MD, Kilany H. MD, Rizk S. MSc. and Kamel G. MD. Lymphocyte Cyclosporine Pharmacokinetic VS. Whole Blood Pharmacokinetic Monitoring: Correlation With Histological Finding. Transplant proc. 2001
83. Masri M.A., PhD, Barbari A., MD, Stephan A., MD, Rizk S., MSc. and Kamel G., MD. Cytokines Gene Polymorphism In a Lebanese Transplant Population And Its Impact On Graft Survival: A One Center Pilot Study. Transplant Proc 2002
- 84. M. Masri, A. Stephan, A. Barbari, S. Rizk, and G. Kamel Pre And Post Transplant Immunological Monitoring Why, When And How? Transplant Proc. 2002**
85. Masri M.A.S,Rizk, A Stephan, A. Barbari. The Pros and Cons of Immunosuppressive drug Monitoring. Transplant Proc.2002
86. Masri MA, Sylvana Rizk, T. Andrysek, V. Matha.cross-reactivity of anti-cyclosporine A monoclonal with its sulphate metabolite: an in vitro study. Molecular Immunology 39: 1059-1060, 2003 .

87. Marwan A. Masri, Mehmet Haberal, Adib Rizvi, Antoine Stephan, Nevzat Bilgin, Anwar Naqvi, Antoine Barbari, Gaby Kamel, Naqi Zafar, Remzi Emiroğlu, Turan Çolak, Kashif Manzoor, Vladimir Matha, Vojtech Kamarad , Sylvana Rizk and Ali Hazieme. The pharmacokinetic of Equoral[®] vs. Neoral[®] in stable renal transplant patients: A multi national multi-center study Transplant Proc. 2004
88. Marwan A. Masri, Tomas Andrysek, Sylvana Rizk and Vladimir Matha. The Role of Generics in transplantation. TM-MMF vs Cellcept in Healthy volunteers. Transplant Proc. 2004.
89. M.A. Masri, M. Haberal, A. Rizvi, A. Stephan, N. Bilgin, A. Naqvi, A. Barbari, G. Kamel, N. Zafar, R. Emiroğlu, T. Çolak, K. Manzoor, V. Matha, V. Kamarad, M. Rots, S. Rizk, A. Hazime, and F. Perlik. Switchability of Neoral and Equoral According to Food and Drug Administration Rules and Regulations. Transplant Proc: 2005
90. An assay for the determination of Sirolimus levels in the lymphocyte of transplant patients. Marwan Masri, Sylvana Rizk , Antoine Barbari, Antoine Stephan, Gaby Kamel and Michael Rost TransMedical Research Institute P.O Box 113-6290 Hamra Beirut Lebanon ,Lebanese Institute of Renal Disease (LIRD), Beirut Lebanon, South Bohemian University, Faculty of Agriculture, Department of Applied Mathematics and Informatics, Ceske Budejovice, Czech Republic. (In Press May 2007 Transplant Proc)
91. A novel assay for the determination of Cyclosporine (CYA) levels in the saliva, dental plaque and the gum biopsy of renal transplant recipients using a patent drug extraction reagent MERI (Beirut Lebanon). Marwan Masri, Samia Abou Jaoude , Sylvana Rizk, Michael Rost , Antoine Barbari, Antoine Stephan, and Gaby Kamel Transmedical Research Institute s.a.l. Beirut Lebanon, the Lebanese university School of Dentistry Beirut Lebanon , South Bohemian University, Faculty of agriculture, Department of Applied Mathematics and Informatics, Ceske Budejovice, Czech Republic and Lebanese Institute of Renal disease (LIRD) Beirut Lebanon. (In Press May 2007 Transplant Proc)
92. Bioavailability of a new generic formulation of Mycophenolate Mofetil MMF 500 (Les laboratoires des Medicaments Sterile Medis Tunisia) vs. CellCept (Roche Switzerland) in adult healthy volunteers. Marwan A. Masri, Sylvana Rizk, Mouez Lidine Elleh Attia, Hanene Barbouch And Michael Rost .TransMedical drug evaluation center Beirut Lebanon Laboratories Medis Tunis and South Bohemian University, Faculty of Agriculture, Department of Applied Mathematics and Informatics, Ceske Budejovice, Czech Republic. (In Press May 2007 Transplant Proc)

Societies:

- 1-Member of the Middle East Society for Organ Transplantation (MESOT).

2-Member of the Arab Society of Nephrology and Kidney Transplantation.

Presentations at International Congresses:

- 1- Lymphocyte Cyclosporine level monitoring. 5th congress of the Arab Nephrology and Renal Transplantation Society. 26-29 November 1997, Beirut-Lebanon.
- 2- Cytokines in transplantation. International conference on Nephrology, Urology, Dialysis and Transplantation, at P.C. Bhurban-Muree (Pakistan). 26-27 August, 2000.
- 3- Pre and Post transplant monitoring. The first congress of the laboratory medicine meeting, Ministry of health, Sanaa-Yamen, April 2001
- 4- Measurement of the immunosuppressive drugs at their site of action: MESOT congress in Ankara Turkey 2004
- 5- Factors influencing the bioavailability of immunosuppressive drugs: Al Jadida Meeting in Morocco 2005

Work Shops performed:

- 1- Training of the central laboratory technician of the Syrian Ministry of health on therapeutic drug monitoring (August 1997)
- 2- Training of laboratory technicians at the Ostrava medical school hospital on therapeutic drug monitoring, Ostrava –Czech republic (September 1999).
- 3- Training of laboratory technicians Ministry of health on therapeutic drug monitoring, Central laboratories, Sanaa-Yamen, (April 2001).
- 4- Validation of Laboratory at Cairo Kidney Center (University of Cairo Sept 2002).
- 5- Set up Therapeutic drug monitoring at Cairo Kidney center (August 2002)
- 6- Validation of Laboratory at Baskant University Hospital Ankara Turkey (November 2002)
- 7- Set up therapeutic drug monitoring in 4 cities in the Islamic republic of Iran 2003-2004

Patents:

3. Method for the monitoring of drugs at their site of action
4. kits to extract drugs from cell and tissue.

Diagnostics:

3. ELISA kits to monitor Cyclosporine in Blood
4. ELISA kits to monitor MPA in blood